Accelerating the journey from hit identification to lead optimization requires a high-throughput in vitro screening platform that can rapidly and cost-effectively characterize your most promising compounds. BioLegacy’s services provide this critical advantage, offering a comprehensive suite of physiologically relevant cell-based assays to elucidate mechanism of action, confirm target engagement, and define your therapeutic’s activity. With advanced analytical capabilities, we deliver robust, decision-driving data to confidently prioritize your development pipeline.
To understand a compound’s therapeutic potential, it is essential to first characterize its activity in a physiologically relevant cellular context. BioLegacy’s in vitro screening platform provides a comprehensive suite of robust, cell-based functional assays designed to deliver clear, quantitative data on your compound’s efficacy and mechanism of action. Leveraging our extensive library of over 350 cancer cell lines, primary cells, and drug-resistant variants, we provide the critical data needed to confidently de-risk your program and select optimal leads.
Demonstrating a clear link between drug exposure, target engagement, and biological response is essential for de-risking your therapeutic and building a compelling case for advancing a candidate. BioLegacy provides comprehensive services for the discovery, validation, and quantitative analysis of pharmacodynamic and disease-related biomarkers. Combined with our extensive bioanalytical capabilities, our in vitro biomarker services confident, data-driven program decisions.
BioLegacy’s sophisticated portfolio of in vitro assays utilizing primary human and animal immune cells rapidly and resolutely characterize the activity of novel immunomodulators and biologics. From T-cell activation to antibody-dependent cellular cytotoxicity, our platforms are engineered to provide definitive insights into your compound’s immunological efficacy and mechanism of action.
When your program demands a unique methodological approach, our team of expert scientists provides comprehensive custom assay development services, from initial concept to a fully validated, screen-ready assay. With our in-house bioanalytical and clinical pathology platforms at your disposal, we ensure that every study is supported by the robust, quantitative biomarker and safety data needed for clear interpretation.
Trust BioLegacy’s in vitro screening for thorough hit-to-lead optimization.